| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6100523 | Journal of Crohn's and Colitis | 2010 | 8 Pages |
Abstract
BDP induces response or remission in two thirds of active UC patients, with a good safety profile. Patients with mild to moderate, left-sided or extensive UC, receiving BDP for more than 4Â weeks are most likely to benefit from this treatment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Tiago Nunes, Manuel Barreiro-de Acosta, Pilar Nos, Ignacio Marin-Jiménez, Fernando Bermejo, Daniel Ceballos, Eva Iglesias, Silvia Gomez-Senent, Yolanda Torres, Angel Ponferrada, José A. Arevalo, Vicent Hernandez, Xavier Calvet, Daniel Ginard,